Antibody Shows Positive Results in Hep C Trial

Article

REHOVOT, Israel-Officials from XTL Biopharmaceuticals are reporting positive results of the first monoclonal antibody to treat hepatitis C (HCV).

XTL-002, the company's monoclonal antibody, has been tested in Phase 1a studies and has reportedly reduced HCV and RNA levels in more than half the patients treated with one dose.

There were no serious adverse effects reported of the intravenous infusions. XTL-002 is a human high-affinity monoclonal antibody.

Hepatitis C is a viral bloodborne disease that attacks the liver and can cause jaundice, fatigue, pain, and vomiting. It can lead to liver damage and cancer. There are an estimated 4 million Americans who have the virus.

XLT Biopharmaceuticals is working on a group of therapies designed to fight a variety of chronic viral infections, drug-resistant bacteria, and systemic fungal infections.

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.